Related Experiment Video
Updated: Jun 7, 2025
Author Spotlight: Advancing Pathogen Detection and Disease Assessment in Real-Time Using M-ROSE
Published on: March 1, 2024
[Pneumocystis jirovecii infection prophylaxis in non-HIV infected individuals: Risk assessment and modalitiesw]
Radhika Sood1, Marco Marando1, Pieter-Jan Gijs2
1Service de pneumologie, Hôpitaux universitaires de Genève, 1211 Genève 14.
Abstract:
Pneumocystis jirovecii (PJ), an opportunistic fungus, can have major consequences in terms of morbidity and mortality. These infections occur mainly in immunocompromised patients and are known for their pulmonary tropism (Pneumocystis pneumonia, PCP). While prevention modalities have been studied in HIV-infected populations, evidence is scarce in non-HIV patients. The decision to prescribe prophylaxis for PJ requires assessment of the clinical context, as well as existing risk factors that may predispose an individual to develop PCP. Few indicators exist that are sufficiently sensitive and specific to predict the occurrence of PCP. The decision to use prophylaxis must be made on a case-by-case basis.
Insights
Pneumocystis jirovecii (PJ) infections cause severe lung disease, especially in immunocompromised individuals. Prophylaxis decisions for Pneumocystis pneumonia (PCP) require careful case-by-case evaluation due to limited predictive indicators, particularly in non-HIV patients.
Area of Science:
- Mycology
- Infectious Diseases
- Immunocompromised Host
Context:
- Pneumocystis jirovecii (PJ) is an opportunistic fungal pathogen.
- PJ infections primarily affect immunocompromised individuals, leading to Pneumocystis pneumonia (PCP).
- Limited research exists on PJ prophylaxis in non-HIV immunocompromised populations.
Purpose:
- To highlight the challenges in predicting and preventing Pneumocystis pneumonia (PCP) in non-HIV patients.
- To emphasize the need for individualized risk assessment for PJ prophylaxis.
Summary:
- Pneumocystis jirovecii (PJ) poses significant morbidity and mortality risks, predominantly in immunocompromised patients, causing Pneumocystis pneumonia (PCP).
- While PJ prevention strategies are established in HIV-infected individuals, data for non-HIV patients are scarce.
- Predicting PCP occurrence is difficult due to a lack of sensitive and specific indicators.
Impact:
- Informs clinical decision-making regarding Pneumocystis pneumonia prophylaxis in diverse immunocompromised patient groups.
- Underscores the need for further research into risk stratification and prevention for non-HIV immunocompromised individuals.
- Emphasizes a personalized approach to managing opportunistic fungal infections.
Related Concept Videos
01:25Transmission-based Precautions II: Airborne and Protective Environment
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...
01:30Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:30Pneumonia III: Complications and Assessment
01:30Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
01:27Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Medical History